{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T18:54:57Z","timestamp":1789584897186,"version":"build-2803163510"},"reference-count":28,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2024,6,27]],"date-time":"2024-06-27T00:00:00Z","timestamp":1719446400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J Neuroendocrinology"],"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Peptide receptor radionuclide therapy (PRRT) is an established therapy for metastatic neuroendocrine neoplasms (NEN). The role of PRRT as a neoadjuvant treatment prior to surgery or other local therapies is uncertain. This scoping review aimed to define the landscape of evidence available detailing the utility of PRRT in the neo\u2010adjuvant setting, including the clinical contexts, efficacy, and levels of evidence. A comprehensive literature search of PUBMED, SCOPUS, and EMBASE through to December 2022 was performed to identify reports of PRRT use as neoadjuvant therapy prior to local therapies. Observational studies and clinical trials were included. A total of 369 records were identified by the initial search, and 17 were included in the final analysis, comprising 179 patients treated with neoadjuvant PRRT. Publications included case reports, retrospective cohort series and a phase 2 trial. Definitions of unresectable disease were variable. Radioisotopes used included\n                    <jats:sup>177<\/jats:sup>\n                    Lu (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u2009142) and\n                    <jats:sup>90<\/jats:sup>\n                    Y (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200936), used separately (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u2009178) or in combination (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u20091). A combination of PRRT with chemotherapy was also explored (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u20092). Toxicity data was reported in 11\/17 studies. Survival analysis was reported in 3\/17 studies. Surgical resection following PRRT was reported for both the primary tumor (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200971) and metastases (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200912). Resection rates could not be calculated as not all publications reported whether resection was completed. Published literature exploring the use of PRRT in the neoadjuvant setting is mostly limited to case reports and retrospective cohort studies. From these limited data there is reported to be a role of PRRT in neoadjuvant setting in the literature. However, the low quality of evidence precludes any definite conclusion on the grade of disease, site of primary, isotope used or use of concomitant chemotherapy that can benefit from this application. Further prospective studies will require collaboration between multiple centers to gain sufficient high\u2010quality evidence.\n                  <\/jats:p>","DOI":"10.1111\/jne.13425","type":"journal-article","created":{"date-parts":[[2024,6,27]],"date-time":"2024-06-27T22:28:59Z","timestamp":1719527339000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Role of neoadjuvant peptide receptor radionuclide therapy in unresectable and metastatic gastro\u2010entero\u2010pancreatic neuroendocrine neoplasms: A scoping review"],"prefix":"10.1111","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1007-974X","authenticated-orcid":false,"given":"Raghava","family":"Kashyap","sequence":"first","affiliation":[{"name":"Department of Molecular Imaging and Therapeutic Nuclear Medicine Peter MacCallum Cancer Centre  Melbourne Victoria Australia"},{"name":"The Sir Peter MacCallum Department of Oncology The University of Melbourne  Melbourne Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Senthil","family":"Raja","sequence":"additional","affiliation":[{"name":"VPS Lakeshore Hospital  Kochi Kerala India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajay","family":"Adusumilli","sequence":"additional","affiliation":[{"name":"coGuide Academy  Bengaluru India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murali Mohan Reddy","family":"Gopireddy","sequence":"additional","affiliation":[{"name":"Global Lead Evidence coGuide Academy  Bengaluru India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin P. T.","family":"Loveday","sequence":"additional","affiliation":[{"name":"Cancer Surgery, Peter MacCallum Cancer Centre  Melbourne Victoria Australia"},{"name":"Hepatobiliary and Upper Gastrointestinal Unit, Royal Melbourne Hospital  Melbourne Victoria Australia"},{"name":"Department of Surgery University of Melbourne  Melbourne Victoria Australia"},{"name":"Department of Surgery University of Auckland  Auckland New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramin","family":"Alipour","sequence":"additional","affiliation":[{"name":"Department of Molecular Imaging and Therapeutic Nuclear Medicine Peter MacCallum Cancer Centre  Melbourne Victoria Australia"},{"name":"The Sir Peter MacCallum Department of Oncology The University of Melbourne  Melbourne Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace","family":"Kong","sequence":"additional","affiliation":[{"name":"Department of Molecular Imaging and Therapeutic Nuclear Medicine Peter MacCallum Cancer Centre  Melbourne Victoria Australia"},{"name":"The Sir Peter MacCallum Department of Oncology The University of Melbourne  Melbourne Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,6,27]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.0589"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1159\/000080731"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neo.2017.09.002"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/819193"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/ags3.12623"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12957-023-02973-3"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607427"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00572-6"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.3390\/ph12030114"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1530\/EDM\u201018\u20100015"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2015.01.007"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.15.5867"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2011.08.006"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/ans.12854"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1097\/RLU.0000000000000805"},{"key":"e_1_2_10_17_1","first-page":"137","article-title":"Case report of a patient with initially inoperable well\u2010differentiated midgut neuroendocrine tumor (WDNT)\u2014PRRT and long\u2010acting somatostatin analogs as the neoadjuvant therapy","volume":"15","author":"Sowa\u2010Staszczak A","year":"2012","journal-title":"Nucl Med Rev Cent East Eur"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-021-02662-9"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2011.08.129"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-020-02341-1"},{"key":"e_1_2_10_21_1","first-page":"254","article-title":"Peptide receptor radionuclide therapy (PRRT) a novel option as neoadjuvant therapy for pancreatic neuroendocrine tumors: a surgical series","volume":"108","author":"Miotto","year":"2019","journal-title":"Neuroendocrinology"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.687925"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.120.258772"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.surg.2017.11.007"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-011-1835-8"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.115.158899"},{"key":"e_1_2_10_27_1","unstructured":"Di MauroS NicoliniT IbrahimM MontiM L. BelliG PaganelliSSSCLLETF.Neoadjuvant PRRT with 177Lu\u2010DOTATATE in non\u2010functioning G1\/2 p\u2010NET patients not candidate for primary surgery: Preliminary toxicity and activity data from a phase. In:Annual Congress of theEuropean Association of Nuclear MedicineOctober 13 \u2013 17 2018D\u00fcsseldorf Germany. IRCCS IRST Meldola ITALY 2Azienda Ospedaliera Universitaria Integrata Verona Italy.2018 p. S186."},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2021.0017"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.09.719"}],"container-title":["Journal of Neuroendocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jne.13425","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T19:15:56Z","timestamp":1748805356000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jne.13425"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,27]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["10.1111\/jne.13425"],"URL":"https:\/\/doi.org\/10.1111\/jne.13425","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.1111\/JNE.13425\/v3\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/JNE.13425\/v2\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/JNE.13425\/v3\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/JNE.13425\/v2\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/JNE.13425\/v1\/review3","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/JNE.13425\/v1\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/JNE.13425\/v2\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/JNE.13425\/v1\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/JNE.13425\/v1\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/JNE.13425\/v2\/review2","asserted-by":"object"}]},"ISSN":["0953-8194","1365-2826"],"issn-type":[{"value":"0953-8194","type":"print"},{"value":"1365-2826","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,27]]},"assertion":[{"value":"2024-02-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-06-11","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-06-27","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e13425"}}